Staging and Treatment of Renal Cell Carcinoma

Diagnosis and Initial Evaluation

• More than 50% of renal cell carcinomas are detected incidentally through abdominal imaging, while others present with symptoms like flank pain, gross hematuria, or palpable abdominal mass, according to the European Association of Urology 1, 2
• Initial laboratory evaluation should include serum creatinine, hemoglobin, leukocyte and platelet counts, lactate dehydrogenase, C-reactive protein, and serum-corrected calcium, as recommended by the American Urological Association 2, 3
• Diagnosis is typically suggested by ultrasonography and confirmed by CT scan, which allows assessment of local invasiveness, lymph node involvement, and metastases, as stated by the National Comprehensive Cancer Network 2, 4
• For accurate staging, contrast-enhanced chest, abdominal, and pelvic CT is mandatory, according to the European Society for Medical Oncology 3, 4
• MRI provides additional information when investigating local advancement and venous tumor thrombus involvement, as recommended by the American College of Radiology 3, 5

TNM Staging System

• The TNM 2009 staging system for renal cell carcinoma includes primary tumor (T), regional lymph nodes (N), and distant metastasis (M) classifications, as defined by the International Union Against Cancer 6

Primary Tumor (T)

• T1: Tumor ≤7 cm, limited to kidney, with T1a: ≤4.0 cm and T1b: >4.0 cm but ≤7.0 cm, as classified by the American Joint Committee on Cancer 5
• T2: Tumor >7.0 cm, limited to kidney, with T2a: >7 cm but ≤10 cm and T2b: >10 cm, as classified by the American Joint Committee on Cancer 5
• T3: Tumor extends to major veins or perinephric tissues but not beyond Gerota fascia, with T3a: invasion into renal vein or perirenal/renal sinus fat, T3b: tumor extends into vena cava below diaphragm, and T3c: tumor extends into vena cava above diaphragm or invades vena cava wall, as classified by the International Union Against Cancer 1
• T4: Tumor invades beyond Gerota fascia or into ipsilateral adrenal gland, as classified by the International Union Against Cancer 1

Regional Lymph Nodes (N)

• N0: No regional lymph node metastasis, as classified by the International Union Against Cancer 1
• N1: Metastasis in a single regional lymph node, as classified by the American Joint Committee on Cancer 5
• N2: Metastases in more than one regional lymph node, as classified by the American Joint Committee on Cancer 5

Distant Metastasis (M)

• M0: No distant metastasis, as classified by the American Joint Committee on Cancer 5
• M1: Distant metastasis, as classified by the American Joint Committee on Cancer 5

Prognostic Assessment

• The 5-year survival rates are approximately 96% for stage I, 82% for stage II, 64% for stage III, and 23% for stage IV disease, according to the National Comprehensive Cancer Network 7
• Risk assessment models such as the MSKCC (Memorial Sloan-Kettering Cancer Center) model categorize patients into favorable, intermediate, or poor risk groups based on factors like Karnofsky performance status, lactate dehydrogenase, serum hemoglobin, corrected serum calcium, and time from diagnosis to treatment, as recommended by the European Society for Medical Oncology 6

Treatment Approaches

Localized Disease (Stages I-III)

• Surgical resection is the standard of care for localized renal cell carcinoma, as recommended by the American Urological Association 6, 7
• Partial nephrectomy is recommended for tumors <4 cm (T1a), as stated by the National Comprehensive Cancer Network 7, 6
• Radical nephrectomy is preferred for larger tumors or when the tumor extends into the inferior vena cava, as recommended by the European Association of Urology 7, 6
• Laparoscopic radical nephrectomy is standard for large tumors, while open partial nephrectomy is standard for small tumors (<4 cm), as stated by the American Urological Association 6
• Minimally invasive techniques such as radiofrequency ablation (RFA) and cryotherapy are under investigation for small renal masses, particularly in patients who are not surgical candidates, as recommended by the National Comprehensive Cancer Network 7, 6
• Lymph node dissection is recommended for patients with enlarged lymph nodes on imaging, as stated by the European Society for Medical Oncology 7

Advanced/Metastatic Disease (Stage IV)

• Cytoreductive nephrectomy should be considered as standard of care for patients with metastatic renal cell carcinoma but should not be performed indiscriminately, as recommended by the European Society for Medical Oncology 8
• Metastasectomy may be an option, particularly for patients with solitary metastases, as stated by the American Society of Clinical Oncology 8, 6
• Radiotherapy is recommended for palliation, especially for symptomatic bone metastases, as recommended by the European Society for Medical Oncology 8, 6

Systemic Therapy for Advanced RCC

• For clear cell renal cell carcinoma (most common subtype, 70-85% of cases):
  • First-line therapy for good and intermediate risk patients: sunitinib or combination of bevacizumab and interferon-α, as recommended by the European Society for Medical Oncology 8
  • First-line therapy for poor risk patients: temsirolimus, as stated by the National Comprehensive Cancer Network 8
  • Second-line therapy after cytokine failure: sorafenib, as recommended by the European Society for Medical Oncology 8
  • Second-line therapy after tyrosine kinase inhibitor failure: everolimus, as stated by the National Comprehensive Cancer Network 8

Follow-up Recommendations

• The European Society for Medical Oncology recommends follow-up intervals of every 3-6 months for the first 2 years for high-risk patients, as stated by the European Society for Medical Oncology 5
• During systemic therapy, 2-4 month follow-up intervals with imaging are recommended for patients with metastatic renal cell carcinoma, as recommended by the European Society for Medical Oncology 5

Special Considerations

• Genetic counseling should be considered for patients ≤46 years of age and for those with multifocal or bilateral renal masses, as recommended by the American Urological Association 1, 4
• Renal tumor biopsy provides histopathological confirmation of malignancy and is recommended before ablative therapies

Diagnosis and Staging of Stage II Renal Cell Carcinoma

Clinical Presentation

• More than half of Stage II RCC cases are discovered incidentally during abdominal imaging performed for unrelated reasons. 9
• The classic triad of flank pain, gross hematuria, and a palpable abdominal mass is now uncommon but may still be present. 10
• Paraneoplastic syndromes such as hypercalcemia, unexplained fever, erythrocytosis, or Stauffer’s syndrome can accompany Stage II RCC. 11
• Symptoms of distant disease (e.g., bone pain or pulmonary nodules) may indicate metastatic involvement. 9

Baseline Laboratory Evaluation

• Measurement of the erythrocyte sedimentation rate (ESR) is recommended as part of the baseline work‑up for suspected RCC. 12

Imaging Protocol

Initial Assessment

• Ultrasonography can suggest the presence of a renal mass but cannot reliably stage the tumor. 10

Definitive Staging Imaging

• Contrast‑enhanced CT of the chest, abdomen, and pelvis is mandatory for accurate staging of RCC. It evaluates tumor size, confinement to the kidney, local invasiveness, nodal status, and distant metastases. 9
• Tumor size criteria on CT: > 7 cm ≤ 10 cm corresponds to T2a; > 10 cm corresponds to T2b. 13
• Confinement to the kidney is defined by the absence of extension beyond Gerota’s fascia. 13
• Evidence of local invasion into perirenal fat or the renal sinus on CT indicates a higher stage (T3a). 10
• Assessment of regional lymph nodes and distant metastases (including pulmonary lesions) is performed with the same CT protocol. [10][9]

MRI as an Adjunct or Alternative

• MRI is recommended when evaluating venous tumor thrombus or when iodinated contrast is contraindicated; it provides staging accuracy comparable to CT. 12

Imaging Not Routinely Required

• Bone scintigraphy, brain CT/MRI, and FDG‑PET are not recommended for initial staging unless specific clinical or laboratory findings suggest involvement of those sites. 12

Histopathological Confirmation

Indications for Core Needle Biopsy

• Core needle biopsy should be performed before ablative therapies, in metastatic disease prior to systemic treatment, and when imaging findings are equivocal and would alter management. The procedure has high sensitivity and specificity. 12

Situations Where Biopsy May Be Deferred

• For patients who are surgical candidates and have classic imaging features of RCC, definitive histopathology can be obtained from the nephrectomy specimen without prior biopsy. 12

Safety and Diagnostic Accuracy

• Complications from renal mass biopsy are rare; tumor seeding is exceptional. 11
• Diagnostic accuracy of core needle biopsy exceeds 90 %. 12

TNM Staging Criteria for Stage II (2009 Classification)

• T2a: Tumor > 7 cm ≤ 10 cm, confined to the kidney.
• T2b: Tumor > 10 cm, confined to the kidney.
• N0: No regional lymph‑node metastasis.
• M0: No distant metastasis. 13

Diagnostic Pitfalls

• The defining feature of Stage II RCC is confinement of a tumor larger than 7 cm to the kidney; any extension beyond the kidney changes the stage. 13
• Extension into perirenal or renal sinus fat (even without breaching Gerota’s fascia) upgrades the disease to Stage III (T3a). 13
• Invasion of major renal veins or the inferior vena cava upgrades to Stage III (T3a‑c). 13
• Extension beyond Gerota’s fascia classifies the tumor as Stage IV (T4). 13
• Chest CT is the most sensitive modality for detecting pulmonary metastases, which would upstage the disease to Stage IV. 12